Arena Pharmaceuticals (ARNA) : The consensus on Arena Pharmaceuticals (ARNA) based on 4 analyst recommendation on the company stock is 2.25, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst also believes that the downside risk to the stock is higher and suggests a Sell on Arena Pharmaceuticals (ARNA).
Arena Pharmaceuticals (ARNA) : 2 investment research analysts covering Arena Pharmaceuticals (ARNA) have an average price target of $3.75 for the near short term. The highest target price given by the Brokerage Firm to the stock is $4 and the lowest target is $4 for the short term. Analysts expect the variance to be within $0.35 of the average price.
Shares of Arena Pharmaceuticals, Inc. rose by 1.82% in the last five trading days and 1.2% for the last 4 weeks. Arena Pharmaceuticals, Inc. is up 3.07% in the last 3-month period. Year-to-Date the stock performance stands at -11.58%. Arena Pharmaceuticals (NASDAQ:ARNA): The stock was completely flat for the day, closing at $1.68 on Tuesday. The flat closing masks the intraday volatility in the stock. After opening at $1.70, the stock touched an intraday high of $1.70 and a low of $1.66. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $1.68. The total trading volume on Tuesday was 1,403,152.
Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors (GPCRs). The Companys drug, BELVIQ (lorcaserin HCl), was approved by the United States Food and Drug Administration for marketing in the United States. In addition to BELVIQ, the Company has other drug candidates and compounds at various stages of research and development. The Company is exploring lorcaserins once-a-day, extended release formulation, as an aid to smoking cessation, in combination with phentermine and other agents for weight management, and for other possible indications. The Companys other drug candidates include ralinepag for vascular diseases, APD334 for autoimmune diseases, APD371 for pain and fibrotic diseases, and temanogrel for thrombotic diseases.